Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M

Enanta Pharmaceuticals reports 2018 executive compensation

By ExecPay News

Published: January 18, 2019

Enanta Pharmaceuticals reported fiscal year 2018 executive compensation information on January 18, 2019.
In 2018, five executives at Enanta Pharmaceuticals received on average a compensation package of $2.1M, a 5% decrease compared to previous year.
Average pay of disclosed executives at Enanta Pharmaceuticals
Jay R. Luly, Chief Executive Officer, received $4.5M in total, which increased by 5% compared to 2017. 59.54% of Luly's compensation, or $2.7M, was in option awards. Luly also received $355.7K in non-equity incentive plan, $611.2K in salary, $838.5K in stock awards, as well as $18.9K in other compensation.
Yat Sun Or, Chief Scientific Officer, received a compensation package of $1.5M, which decreased by 14% compared to previous year. 41.39% of the compensation package, or $630.9K, was in option awards.
Nathalie Adda, Chief Medical Officer, earned $1.5M in 2018, a 14% decrease compared to previous year.
Paul J. Mellett, Chief Financial Officer, received $1.4M in 2018, which decreases by 11% compared to 2017.
Nathaniel S. Gardiner, General Counsel, earned $1.4M in 2018, a 9% decrease compared to previous year.
Enanta Pharmaceuticals' fiscal year ends on September 30.

Related executives

Jay Luly

Enanta Pharmaceuticals

Chief Executive Officer

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

Nathalie Adda

Enanta Pharmaceuticals

Chief Medical Officer

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

You may also like

Source: SEC filing on January 18, 2019.